Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Lord Sharkey, and are more likely to reflect personal policy preferences.
A Bill to establish an inquiry into the events surrounding the creation of mortgage prisoners, their consequences and any other relevant matters; and for connected purposes.
A bill to require the Financial Conduct Authority to make rules for authorised persons to owe a duty of care to consumers in their regulated activities
A Bill to make provision for non-interest-bearing student finance facilities.
To give a statutory pardon to Alan Mathison Turing for offences under section 11of the Criminal Law Amendment Act 1885 of which he was convicted on 31 March 1952.
Lord Sharkey has not co-sponsored any Bills in the current parliamentary sitting
Assessments regarding the effectiveness of competition on cross-Solent ferry services are a matter for the Competition and Markets Authority, which is independent of the Government. Decisions on which markets to investigate sit with its board.
The Department continues to engage directly with key stakeholders, including Islanders and ferry companies.
Working under the UK Rare Diseases Framework, the Government is committed to improving the lives of those living with rare diseases. NHS England and the Department are strongly supportive of clinical leadership and recognise the critical need to incorporate clinical expertise into our work. The national clinical directors are a key part of this approach and play an important role in policy development and implementation.
We are currently in the initial phases of scoping and designing a new integrated Department that aims to enhance the efficiency and effectiveness of our healthcare system. As part of this process, we are carefully considering the future role of national clinical directors. While no specific decisions have been made yet, we are open to considering the benefit of appointing a National Clinical Director for Rare Diseases following the integration of NHS England into the Department, subject to funding arrangements.
As we take forward the work to integrate NHS England into the Department, we will continue to analyse and assess impacts of all kinds. This will include putting in place plans to ensure continuity of specialised services, with patient safety at the forefront of our work.
Joint forward plans (JFPs) are produced by integrated care boards (ICBs) and are publicly available on the respective websites of the ICBs. The Government does not hold any central records of these JFPs and there are no plans to place copies of the JFPs in the Library of the House.
NHS England has asked the integrated care boards (ICBs) to act primarily as strategic commissioners of health and care services and to reduce the duplication of responsibilities within their structure, to achieve a 50% cost reduction in their running cost allowance.
We expect ICBs to fully deliver on their commissioning responsibilities, including the responsibility to commission some of the specialised services. Furthermore, ICBs have a legal duty to involve patients and their carers and/or representatives in the planning of services, as well as proposals and decisions that have an impact on services. ICBs are required to set out how they plan to execute this duty in their joint forward plans.
NHS England provided additional guidance to ICBs, National Health Service trusts, and NHS foundation trusts on 1 April 2025, where ICBs were tasked with developing plans by the end of May setting out how they will manage their resources to deliver across their priorities.
NHS England will be working closely with ICBs to support the development of these plans, ensuring that their implementation reduces duplication and supports patient care. In his letter to ICBs, Sir Jim Mackay committed to greater transparency and moving back to a fair shares allocation policy over time.
NHS England has asked the integrated care boards (ICBs) to act primarily as strategic commissioners of health and care services and to reduce the duplication of responsibilities within their structure, to achieve a 50% cost reduction in their running cost allowance.
We expect ICBs to fully deliver on their commissioning responsibilities, including the responsibility to commission some of the specialised services. Furthermore, ICBs have a legal duty to involve patients and their carers and/or representatives in the planning of services, as well as proposals and decisions that have an impact on services. ICBs are required to set out how they plan to execute this duty in their joint forward plans.
NHS England provided additional guidance to ICBs, National Health Service trusts, and NHS foundation trusts on 1 April 2025, where ICBs were tasked with developing plans by the end of May setting out how they will manage their resources to deliver across their priorities.
NHS England will be working closely with ICBs to support the development of these plans, ensuring that their implementation reduces duplication and supports patient care. In his letter to ICBs, Sir Jim Mackay committed to greater transparency and moving back to a fair shares allocation policy over time.
The Department funds research and research infrastructure, which supports patients and the public to participate in high-quality research across the United Kingdom, through the National Institute of Health and Care Research (NIHR).
Development and delivery of research in the pharmaceutical sector is supported and enabled nationwide through NIHR infrastructure, including the NIHR Research Delivery Network, the NIHR Clinical Research Facilities, the NIHR Biomedical Research Centres, and the newly designated NIHR Commercial Research Delivery Centres. These all support the delivery of clinical research through facilities, staff resource, collaborations, and funding.
In order to maximise our potential to be a world leader and develop a more competitive, efficient, and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the UK, to provide innovative treatment options for patients.
On 16 January 2024, under the previous Government, HM Treasury published a consultation proposing changes to the Capital Gains Tax (CGT) rules that apply to alternative financial arrangements. The consultation closed on 9 April 2024 and this Government is carefully considering all responses. A response document will be published in due course.